Hypogonadism is a common condition defined by the presence of low serum testosterone levels and hypogonadal symptoms, and most commonly treated using testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of treatment, along with proper follow-up, are increasingly important given the large increase in testosterone prescriptions and the recent concern for cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and Drug Administration required that testosterone product labels disclose a potential CV risk, despite the evidence base for this association being weak and inconclusive. However, TTh may improve CV outcomes rather than increase risks.
The Medical clinics of North America. 2017 Dec 06 [Epub]
John T Sigalos, Alexander W Pastuszak, Mohit Khera
Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA., Center for Reproductive Medicine, Baylor College of Medicine, 1 Baylor Plaza, Room N730 Houston, TX 77030, USA; Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX 77030, USA., Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX 77030, USA. Electronic address: .